

Poster programme

HPV vaccines

- [P01] **Predictors of HPV vaccine acceptability: A theory-informed systematic review**
N.T. Brewer¹, K.I. Fazekas; *UNC School of Public Health, USA*
- [P02] **Synthesis and assembly of human Papillomavirus type 16 L1 virus-like particles**
S.B. Bazan¹, K.A. Kaires¹, A.M. Cianciarullo³, M..LS. Oliveira⁴, P.L. Ho¹; ¹*Instituto de Química da Universidade de São Paulo, Brazil*, ²*Instituto de Ciências Biomédicas da Universidade de São Paulo, Brazil*, ³*Laboratório de Genética do Instituto Butantan, Brazil*, ⁴*Centro de Biotecnologia do Instituto Butantan, Brazil*
- [P03] **An evidence-based approach for informing adolescents about HPV vaccination**
L.A. Vallely^{*}, S.A. Roberts, H.C. Kitchener, L. Brabin; *University of Manchester, UK*
- [P04] **Investigations on a possible cervical cancer immunotherapy by human dendritic cells pulsed with *Nicotiana benthamiana* HPV-16 E7 extract**
F. Grasso¹, P. Di Bonito¹, G. Mangino¹, S. Massa¹, E. Illiano¹, R. Franconi¹; ¹*Istituto Superiore Di Sanità, Italy*, ²*Università di Roma Tre, Italy*, ³*ENEA Casaccia, Italy*
- [P05] **High prevalence of human Papillomavirus infection with a wide spectrum of HPV genotypes among Italian HIV-1 infected subjects**
E. Tanzi¹, G. Orlando², A. Amendola¹, S. Bianchi¹, R. Beretta², M.M. Fasolo²; ¹*University of Milan, Italy*, ²*L Sacco Hospital, Italy*
- [P06] **Cost-effectiveness of Human Papilloma Virus (HPV) 16/18 Vaccines against cervical cancer in the Netherlands**
M.J. Postma¹, H.W. Nijman², C.A.H.H. Daemen², T.A. Westra¹, A.G.J. van der Zee², J.C. Wilschut¹; ¹*Groningen Research Institute of Pharmacy (GRIP), The Netherlands*, ²*University Medical Centre Groningen (UMCG), The Netherlands*

TB vaccines

- [P07] **The dynamic hypothesis of latent tuberculosis infection is the rational that supports RUTI, a therapeutic vaccine design to shorten its treatment**
P.J. Cardona¹, I. Amat²; ¹*Institut per a la Investigació en Ciències de la Salut Germans Trias i Pujol, Spain*, ²*Archivel Farma, s.l., Spain*
- [P08] **Protection imparted by anti-IL-4 antibody in a murine model of *M. tuberculosis* infection: a potential immunotherapeutic agent?**
E. Roy¹, J. Brennan², S. Jolles¹, D.B. Lowrie¹; ¹*Cardiff University, UK*, ²*National Institute for Medical Research, UK*

Cancer vaccines

- [P09] **Functional reconstruction of structurally complex epitopes using clips-technology**
P. Timmerman¹, W.C. Puijk¹, R.H. Meloen¹; ¹*Pepscan Therapeutics BV, Netherlands*
- [P10] **Monitoring cell hybridoma yields with confocal microscopy**
M Gabrijel¹, U Repnik¹, M Krefl¹, M Jeras¹, R Zorec¹; ¹*Faculty of Medicine, Slovenia*, ²*Celica Biomedical Sciences Center, Slovenia*, ³*Blood Transfusion Centre of Slovenia, Slovenia*
- [P11] **Peptide-based immunotherapy strategy in EBV latency II malignancies**
O. Moralès¹, S. Depil¹, F.A. Castelli⁵, N. Delhem¹, V. François¹, B. Georges¹; ¹*Institut de Biologie de Lille, France*, ²*Service des Maladies du Sang, France*, ³*EFS Nord de France, France*, ⁴*CHU Lille, France*, ⁵*CEA Saclay, France*, ⁶*Hoffman-Laroche Inc., USA*
- [P12] **Design of a CRIPTO AutoVac™ vaccine for the treatment of cancer**
T. Jensen^{*}, L.S. Harlow, F.S. Nielsen, B. Voldborg, C. Dyring, A. Neisig; *Pharmexa A/S, Denmark*

Adjuvants

- [P13] Poster withdrawn
- [P14] **Effect of chitosan encapsulation conditions on immunogenicity of Diphtheria toxoid as a mucosal carrier for intranasal administration in Guinea pig**
A. Rezaei Mokarram¹, S.A.R. Mortazavi², N. Mohammadpour Dunighi³, H. Zolfagharian³, A. Saffar Shahroodi⁴; ¹*Razi Vaccine and Serum Research Institute, Iran*, ²*Shaheed Beheshti University of Medical Sciences and Health Services, Iran*, ³*Razi Vaccine and Serum Research Institute, Iran*, ⁴*Iranian Institute for Health Sciences Research, Iran*
- [P15] **Investigating the use of a short peptide of Zonula Occludens Toxin (Zot) as an adjuvant for transcutaneous delivery of tetanus toxoid**
L. Coombes¹, P. Stickings¹, A.P. Tamiz², D. Sesardic¹; ¹*National Institute For Biological Standards and Control, UK*, ²*Alba Therapeutics, USA*

[P16]	Protective efficacy of vaccine preparations based on different adjuvant systems and HBV antigens in Marmota Monax Model S. Catone ^{*1} , E. D'Ugo ¹ , A. Canitano ¹ ; ¹ <i>Istituto Superiore di Sanità, Italy</i> , ² <i>Berna Biotech Ltd, Switzerland</i>
[P17]	Improvement of vaccines against Bordetella pertussis by LPS modifications P. van der Ley ^{*1} , J. Geurtsen ¹ , R. Vandebriel ² , G. Akkerman ¹ , H.J. Hamstra ¹ , L. Steeghs ² ; ¹ <i>Netherlands Vaccine Institute (NVI), The Netherlands</i> , ² <i>Utrecht University, The Netherlands</i> , ³ <i>National Institute of Public Health and the Environment (RIVM), The Netherlands</i>
[P18]	Crossbeta: A novel and safe adjuvation technology for subunit vaccines, using antigen only M.F.B. Gebbink [*] , B. Bouma; <i>Crossbeta Biosciences, The Netherlands</i>
[P19]	Analyses of IgG1 and IgG2a immune responses specific for Ovalbumin in mice adjuvanted with novel PGM-containing montanide ISA formulations L. Habjanec [*] , B. Halassy, J. Tomasic; <i>Institute of Immunology, Croatia</i>
[P20]	Immune response induced by the Recombinant Chaperonin Cpn60 of Bordetella pertussis: Adjuvant and immunogenic activities V.C.B. Cainelli Gebara [*] , A.P.Y. Lopes, P.S. Wolf, V.R.F. Ferreira, W. Quintilio, M.A. Sakauchi, I. Raw; <i>Instituto Butantan, Brazil</i>
[P21]	Performance evaluation of vegetal adjuvants with Gallibacterium anatis vaccines M.E. Vazquez ¹ , L. Castellanos ¹ , D. Orioux ² , C. Gonzalez ^{*1} ; ¹ <i>Boehringer Ingelheim Vetmedica S.A. de C.V., Mexico</i> , ² <i>SEPPIC, France</i>
[P22]	Differential activation of human and mouse toll-like receptor 4 by the adjuvant candidate LpxL1 Lipopolysaccharide of Neisseria meningitidis L. Steeghs ^{*1} , M. Keestra ¹ , H. Uronen-Hansson ² , A. van Mourik ¹ , P. van der Ley ³ , J. van Putten ¹ ; ¹ <i>University of Utrecht, The Netherlands</i> , ² <i>Institute of Child Health, UK</i> , ³ <i>Netherlands Vaccine Institute, The Netherlands</i>
[P23]	Adjuvant for live adenovirus vaccines O.J.A.E. Ophorst ^{*1} , K. Radosevic ¹ , A. Lemckert ¹ , J. Goudsmit ¹ , M. Havenga ¹ ; ¹ <i>Crucell Holland BV, Leiden, The Netherlands</i> , ² <i>Center of Poverty-related Communicable Diseases, Academic Medical Center Amsterdam, The Netherlands</i>
[P24]	Immunostimulation reconstituted influenza virosomes R Zurbriggen [*] ; <i>Pevion Biotech, Switzerland</i>
[P25]	Agonists to intracellular toll-like receptors can augment the immune response to the Yersinia pestis plague vaccine in BALB/c mice K. Amemiya ^{*1} , J.L. Meyers ¹ , T. Rogers ¹ , P.L. Worsham ¹ , B. Powell ¹ , S.L. Norris ¹ ; ¹ <i>USAMRIID, USA</i> , ² <i>Coley Pharmaceutical Group, USA</i>
[P26]	Kinins generated upon vaccination with the QS21 saponin-containing Leishmune® vaccine are partially responsible for induction of protective immunity against visceral leishmaniasis D. Nico, L.N. de Almeida, A.C. Monteiro, J. Scharfstein, C.B. Palatnik-de-Sousa [*] ; <i>Federal University of Rio de Janeiro, Brazil</i>
[P27]	Whole-cell Pertussis vaccine function is mediated by toll-like receptor-4 H.A. Banus ¹ , R.M. Stenger ³ , E.R. Gremmer ¹ , J.A. Dormans ¹ , F.R. Mooi ² , T.G. Kimman ¹ , R.J. Vandebriel ^{*1} ; ¹ <i>National Institute of Public Health and the Environment, The Netherlands</i> , ² <i>Netherlands Vaccine Institute, The Netherlands</i>
[P28]	Poster withdrawn
Influenza vaccines	
[P29]	Influenza vaccination coverage among children with and without high-risk medical conditions S. Esposito ^{*1} , A. Porta ¹ , C. Pelucchi ² , G. Marseglia ³ , D. De Mattia ⁴ , M.E. Di Cosimo ⁵ ; ¹ <i>University of Milan, Italy</i> , ² <i>Mario Negri Institute, Italy</i> , ³ <i>University of Pavia, Italy</i> , ⁴ <i>University of Bari, Italy</i> , ⁵ <i>Primary Care Pediatrician, Italy</i>
[P30]	Effectiveness of influenza vaccination in children with Asthma S. Esposito ^{*1} , A. Porta ¹ , C. Pelucchi ² , G. Marseglia ³ , C. Sabatini ¹ , M.E. Di Cosimo ⁴ ; ¹ <i>University of Milan, Italy</i> , ² <i>Mario Negri Institute, Italy</i> , ³ <i>University of Pavia, Italy</i> , ⁴ <i>Primary Care Pediatricians, Italy</i>
[P31]	Concomitant administration of ZOSTAVAX® and Influenza vaccine in adults ≥50 years old B. Kerzner ^{*1} , A.V. Murray ² , E. Cheng ³ , R. Ifle ⁴ , P.R. Harvey ⁵ ; ¹ <i>Health Trends Research, USA</i> , ² <i>PharmQuest, USA</i> , ³ <i>State University of New York, USA</i> , ⁴ <i>Behandelcentrum, The Netherlands</i> , ⁵ <i>Crouch Oak Family Practice, UK</i> , ⁶ <i>Sequani Clinical, UK</i> , ⁷ <i>Merck Research Labs, USA</i>
[P32]	Intradermal influenza vaccination offers superior immunogenicity compared with conventional vaccine in the elderly, and is safe after two annual vaccinations in adults I. Leroux-Roels ^{*1} , G. Leroux-Roels ¹ , D. Holland ² , R. Booy ³ , F. Weber ⁴ , M. Saville ⁴ ; ¹ <i>Center for Vaccinology, Belgium</i> , ² <i>Centre for Clinical Research and Effective Practice, New Zealand</i> , ³ <i>National Centre for Immunization Research and Surveillance, Australia</i> , ⁴ <i>Sanofi Pasteur, France</i>
[P33]	Long-term immunogenicity of a virosome-adjuvanted subunit inactivated Influenza vaccine in children with Asthma G.V. Zuccotti [*] , A Amendola, A Viganò, E Pariani, A Zappa; <i>University of Milan, Italy</i>

[P34]	Virus-host cell interactions in a vaccine production process: Proteomic analysis of influenza A virus infected mammalian cells by 2D-DIGE D. Vester* ¹ , E. Rapp ² , Y. Genzel ² , D. Gade ² , U. Reichl ¹ ; ¹ <i>Otto-von-Guericke-University Magdeburg, Germany</i> , ² <i>Max Planck Institute for Dynamics of Complex Technical Systems, Germany</i>
[P35]	Purification of whole-virion influenza vaccines: A focus on residual DNA B. Kalbfuss* ¹ , A. Knöchlein ² , T. Kröber ³ , K. Eisold ⁴ , U. Reichl ¹ ; ¹ <i>MPI for Dynamics of Complex Technical Systems, Germany</i> , ² <i>University of Applied Sciences Hamburg, Germany</i> , ³ <i>Martin Luther University Hall-Wittenberg, Germany</i> , ⁴ <i>University of Applied Sciences Jena, Germany</i> , ⁵ <i>Otto-von-Guericke University, Germany</i>
[P36]	Development of universal Influenza A vaccines using attenuated Bordetella pertussis as antigen delivery R. Li* ¹ , T. Narasaraju, M.C. Phoon, V.T.K. Chow, S. Alonso; <i>National University of Singapore, Singapore</i>
[P37]	Cross-reactive antibodies to viruses of both B/Victoria and B/ Yamagata lineages as induced by Influenza vaccination in middle-aged and elderly volunteers A.M. Lorio*, B. Camilloni, E. Lepri, M. Neri; <i>University of Perugia, Italy</i>
[P38]	Higher yields in influenza vaccine production using perfusion in high-density cell culture A. Bock* ¹ , Y. Genzel ¹ , U. Reichl; <i>Max Planck Institute for the Dynamics of Complex Technical Systems, Germany</i> , ² <i>Otto-von-Guericke University, Germany</i>
[P39]	Enhanced immunogenicity of a virosomal vaccine against Avian influenza by adjuvation A. Rodríguez* ¹ , K. Radošević ¹ , R. Mintardjo ¹ , D. Tax ¹ ; ¹ <i>Cruceff Holland BV, The Netherlands</i> , ² <i>Isconova AB, Sweden</i>
[P40]	Crossbeta adjuvation: H5N1 avian influenza case study, addressing dosing problems with subunit vaccines and safety issues with adjuvants B. Bouma*, M.F.B. Gebbink; <i>Crossbeta Biosciences, The Netherlands</i>
[P41]	Pneumo-adaptation of H5N1 Avian influenza virus in mice B. Lambrecht* ¹ , M. Leroy ² , M. Steensels ¹ , H. Lage Ferreira ¹ , D. Desmecht ² , Th. van den Berg ¹ ; ¹ <i>VAR, Belgium</i> , ² <i>University of Liège, Belgium</i>
[P42]	Can vaccination of health care workers prevent Influenza epidemics in hospitals and nursing homes? C. van den Dool* ¹ , J. Wallinga ² , M.J.M. Bonten ¹ , A.M. van Loon ¹ , J.W.J. Lammers ¹ , E. Hak ¹ ; ¹ <i>University Medical Center, The Netherlands</i> , ² <i>National Institute for Public Health and the Environment, The Netherlands</i>
[P43]	Reports of deaths following Influenza immunizations in the 2006/2007 season J. Labadie* ¹ , A.C. van Grootheest; <i>The Netherlands Pharmacovigilance Centre Lareb, The Netherlands</i>
[P44]	What are the determinants of influenza vaccine uptake among health care workers in Dutch nursing homes? I. Looijmans –van den Akker* ¹ , J.J.M. van Delden ¹ , G.A. van Essen ¹ , M.E. Hulscher ² , L.M. A. Muller ¹ , M. van der Sande ³ ; ¹ <i>University Medical Center Utrecht, The Netherlands</i> , ² <i>University Medical Center Nijmegen, The Netherlands</i> , ³ <i>National Institute for Public Health and the Environment (RIVM), The Netherlands</i>
[P45]	Influenza vaccine effectiveness in elderly persons: A 7-year data pooling cohort study from The Netherlands R.H.H. Groenwold* ¹ , A.W. Hoes ¹ , K.L. Nichol ² , E. Hak ¹ ; ¹ <i>University of Utrecht, The Netherlands</i> , ² <i>VA Medical Center, USA</i>
[P46]	Efficacy and immunogenicity of one versus two doses of LAIV in young children C.K. Farhat, H.B. Neto*; <i>Federal University of Sao Paulo, Brazil</i>
[P47]	Shedding and immunogenicity of live attenuated influenza vaccine in subjects 5–49 years of age S.L. Block ¹ , C.S. Ambrose ² , R.E. Walker* ² ; ¹ <i>Kentucky Pediatric Research, USA</i> , ² <i>MedImmune, USA</i>
[P48]	Evaluation of the effect of adjuvants on the immune response induced by influenza split virus vaccine in mice W. Quintillo, E.N. Miyaji*, L.C.C. Leite, I. Raw; <i>Instituto Butantan, Brazil</i>
[P49]	Influenza H5 vaccine: In need of “help” J. Alexander* ¹ , P. Bilsel ¹ , T. Bratt ² , F. Dal Degan ² , J.Katz ³ , M. Newman ¹ ; ¹ <i>Pharmexa-Epimmune, USA</i> , ² <i>Pharmexa A/S, Denmark</i> , ³ <i>Center for Disease Control and Prevention, USA</i>
[P50]	High concentration of formaldehyde in H5N1 Re-1 and Re-4 vaccine: New killer for laying hens Cheng He*, Wanyo Pang, Di Meng, Jian Qiao; <i>China Agricultural University, China</i>
[P51]	Gram positive enhancer matrix (GEM) particles: Novel adjuvant for systemic and mucosal influenza immunizations V. Saluja* ¹ , J-P. Amorij ¹ , K. Leehouts ² , W.L.J Hinrichs ¹ , H.W. Frijlink ¹ ; ¹ <i>University of Groningen, The Netherlands</i> , ² <i>BiOMaDe Technology, The Netherlands</i>
[P52]	Evaluation of Newcastle disease virus vectored H5 avian influenza vaccine in commercial chickens Z. Bu*, J. Ge, G. Tian, H. Chen; <i>Harbin Veterinary Research Institute, China</i>
[P53]	Evaluation of Tetanus toxoid as a positive marker for Avian influenza vaccination of poultry- efficacy in vaccine/H5N1 challenge study C.M. James*, Y.Y. Foong, J.P. Mansfield, S.G. Fenwick, T.M. Ellis; <i>Murdoch University, Australia</i>
[P54]	Effects of annual influenza vaccination on winter mortality in elderly people with chronic heart disease A. Vila-Corcoles*, X. Ansa, C. De Diego, E. Valdivieso, C. Fuentes; <i>Institut Català de la Salut, Spain</i>
[P55]	VESTA : Influenza vaccine coverage for healthcare workers and reasons for observance in French geriatric settings G. Gavazzi* ¹ , Y. Filali Zegzouti ² , A.C. Guyon ² , B. de Wazières ³ , F. Piette ² , M. Rothan-Tondeur ¹ ; ¹ <i>Clinique de Médecine Gériatrique Centre Hospitalier Universitaire de Grenoble, France</i> , ² <i>Hôpital Charles Foix, France</i> , ³ <i>Centre Hospitalier Universitaire de Nîmes, France</i>

- [P56] **VESTA: Two randomized intervention programs to increase health care worker influenza vaccination rates in geriatric settings, two results**
 M. Rothan-Tondeur*¹, Y. Filali Zegzouti¹, A.C. Guyin¹, B. de Wazieres³, F. Piette¹, G. Gavazzi⁴; ¹Hôpital Charles Foix, France, ²Centre Hospitalier Universitaire de Nîmes, France, ³Clinique de Médecine Gériatrique Centre Hospitalier, ⁴Universitaire de Grenoble, France
- [P57] **The adjuvant effects of chicken IL-2, IL-18, IFN-γ and CpG DNA on HA DNA vaccines against H5 subtype of avian influenza virus delivered by attenuated Salmonella**
 Q. Hu, Z. Pan, C. Zhang, X. Liu, X. Jiao*; Yangzhou University, China
- [P58] **Analysis of influenza virus Hemagglutinin N-Glycosylation - influence of upstream process conditions**
 J. Schwarzer*¹, E. Rapp¹, U. Reichl¹; ¹Max Planck Institute for Dynamics of Complex Technical System, Bioprocess Engineering, Germany, ²Otto-von-Guericke-University Magdeburg, Germany
- [P59] **Did the Netherlands influenza vaccination program have an effect on excess mortality during influenza seasons among Dutch elderly?**
 A.G. Jansen¹, E.A. Sanders¹, A.W. Hoes¹, A.M. van Loon¹, K.L. Nichol², E. Hak*¹; ¹University Medical Center Utrecht, The Netherlands, ²VA Medical Center Minneapolis, USA
- [P60] **Safety and reactogenicity of an adjuvanted H5N1 pandemic candidate vaccine in adults aged 18 years and older**
 H. Rumke*¹, J-M. Bayas², J-R. de Juanes³, C. Caso⁴, J.H. Richardus⁵, M. Campins⁶, L. Rombo⁷, X Duval⁸, V. Romanenko⁹, T. F. Schwarz¹⁰, R. Fassakhov¹¹, F. Abad-Santos¹², F. von Sonnenburg¹³, M Dramé¹⁴, R. Saenger¹⁴, W. Ripley Ballou¹⁴; ¹Vaxinostics, The Netherlands, ²Hospital Clinic, Spain, ³Hospital 12 de Octubre, Spain, ⁴Hospital Clínico San Carlos, Spain, ⁵Municipal Public Health Service Rotterdam Rijnmond, The Netherlands, ⁶Hospital Vall d'Hebron, Spain, ⁷Infektionskliniken, Mälarsjukhuset, Sweden, ⁸CIC-Bichat, France, ⁹City Hospital N40, Russia, ¹⁰Stiftung Juliusspital, Germany, ¹¹Kazan Research Institute of Epidemiology and Microbiology, Russia, ¹²Hospital de La Princesa, Spain, ¹³Ludwig Maximilians Universitaet, Germany, ¹⁴GlaxoSmithKline Biologicals, Belgium
- [P61] **Immunogenicity of commonly used influenza vaccines after intranasal and intramuscular vaccination**
 N. Hagenaars*¹, E. Mastrobattista¹, H. Glansbeek², H. Vromans¹, W. Jiskoot⁴; ¹University Utrecht, Netherlands, ²Nobilon International BV, The Netherlands, ³N.V. Organon, The Netherlands, ⁴Leiden/Amsterdam Center for Drug Research, Leiden University, The Netherlands
- [P62] **Influenza vaccination: Is addition of aluminium hydroxide to whole inactivated virus (WIV) vaccine beneficial?**
 L. Bungener, A. de Haan, F.C.G. Geeraedts, W. ter Veer, J. Wilschut, A. Huckriede*; University Medical Centre Groningen, The Netherlands
- [P63] **Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and innate cytokine production by DCs**
 F. Geeraedts*¹, L. Bungener¹, J. Pool¹, J. Wilschut¹, A. Huckriede¹; ¹University Medical Center Groningen, The Netherlands, ²Netherlands Influenza Vaccine Research Center, The Netherlands
- [P64] **Effects of combined influenza and pneumococcal conjugate vaccination and influenza vaccination alone in preventing respiratory infections in children: A randomised double-blind controlled trial**
 A.G.S.C. Jansen*, E.A.M. Sanders, A.W. Hoes, A.M. van Loon, E. Hak; University Medical Center Utrecht, The Netherlands

Process technology

- [P65] Poster withdrawn
- [P66] Poster withdrawn
- [P67] **Influenza vaccine production: Flow cytometric monitoring of apoptosis and virus protein production in mammalian cell culture**
 J. Schulze-Horsel*¹, M. Schulze¹, Y. Genzel¹, U. Reichl¹; ¹Max Planck Institute for Dynamics of Complex Technical Systems, Germany, ²Otto-von-Guericke-University, Germany
- [P68] **The use of novel biochemical, immunological and functional methods to characterize UK Anthrax vaccine and its manufacturing process**
 K. West*, H. Cuthbertson, P. Proud, S. Noonan, R. Baker, S. Charlton; Health Protection Agency, UK
- [P69] **Positional proteomics applied to the profiling of the proteome of Bordetella Pertussis**
 A.P. de Jong*¹, D. Lambermont, B. van der Waterbeemd; Netherlands Vaccine Institute, The Netherlands
- [P70] **Multivariate data analysis of polio vaccine production at different scales for improved process understanding**
 W.A.M. Bakker, Y.E. Thomassen*, L.A. Van der Pol; Netherlands Vaccine Institute, The Netherlands
- [P71] **New Pertussis vaccines for developing countries**
 W.O. Dias*, D.S.P.Q. Horton, M.A. Sakauchi, F.S. Kubrusly, D Iourtov, N. Furuyama; Instituto Butantan, Brazil
- [P72] **From process understanding to process control: Application of PAT in vaccine process development**
 M. Streefland*¹, B. Van de Waterbeemd¹, P. Van Herpen¹, E.C. Beuvery², L.A. Van der Pol¹, DE Martens³; ¹Netherlands Vaccine Institute, The Netherlands, ²PAT Consultancy, The Netherlands, ³Wageningen University, The Netherlands

Delivery systems

- [P73] **Diphtheria toxoid-containing microparticulate powder formulations for pulmonary vaccination**
M. Amidi¹, H. Pellikaan², G.F.A. Kersten³, A.H. de Boer⁴, W. Jiskoot^{*1}; ¹*Utrecht University, Netherlands*, ²*Weesp, The Netherlands*, ³*NVI, The Netherlands*, ⁴*University of Groningen, The Netherlands*, ⁵*Leiden University, The Netherlands*
- [P74] **New prokaryotic vectors for antigen display**
R. Sartorius, A. Caivano, M. Trovato, C. Bettua, A Citro, G. Del Pozzo, D. Lauman, N Haigwood, P. De Berardinis*; *CNR, Italy*
- [P75] **Nasal immunization studies in rabbits by anionic and Chitosan coated liposomes encapsulated with Tetanus toxoid as a model antigen**
M. Tafaghodi*, M-R Jaafari, M-R Amin; *Mashhad University of Medical Sciences (MUMS), Iran*
- [P76] **Biodegradable nanoparticles induce antigen-specific T cell response through dendritic cell maturation**
T. Uto^{*1}, X. Wang¹, T. Akagi², R. Zenkyu¹, M. Akashi², M. Baba¹; ¹*Kagoshima University, Japan*, ²*Osaka University, Japan*, ³*CREST JST, Japan*
- [P77] **Follicular targeting: From skin explant to transcutaneous vaccination in humans**
A. Vogt¹, B. Mahé², U. Blume-Peytavi¹, B. Combadière^{*3}; ¹*Université Pierre et Marie Curie, France*, ²*INSERM U543, France*, ³*Clinical Research Center for Hair and Skin Physiology, Germany*
- [P78] **Impact of the route of immunization on modified Vaccinia virus Ankara-elicited immune responses**
V. Abadie*, O. Bonduelle, D. Duffy, B. Combadière; *INSERM U543, France*
- [P79] **An engineered attenuated Escherichia coli for the stimulation of mucosal immunity**
L.Thomas^{*1}, S. Goussard¹, C. Grillot-Courvalin; *Institute Pasteur, France*
- [P80] **Amphiphilic poly(amino acid) nanoparticles as a carrier and adjuvant for protein-based vaccines**
T. Akagi^{*1}, X. Wang², T. Uto², M. Baba², M. Akashi¹; ¹*Osaka University, Japan*, ²*Kagoshima University, Japan*, ³*JST-CREST, Japan*
- [P81] **Improved vaccines against influenza and other pathogens based on adjuvantation and delivery with a novel polycationic sphingolipid – CCS: Immunogenicity and efficacy studies in animal models**
E. Kedar^{*1}, Y. Barenholz¹, S. Samira²; ¹*Hebrew University, Israel*, ²*Nasvax, Israel*
- [P82] **In vivo primary activation of CD4⁺ and CD8⁺ T-Cells following mucosal vaccination**
D. Medagliani*, A. Ciabattini, E. Pettini, A.M. Cuppone, G. Pozzi; *Università di Siena, Italy*
- [P83] **Chitosan: Poloxamer nanoparticles as delivery vehicles for nasal delivery of Hepatitis B surface antigen**
C. Prego^{*1}, P. Paolicelli², A. Sanchez², M.J. Alonso²; ¹*Massachusetts Institute of Technology, USA*, ²*University of Santiago de Compostela, Spain*
- [P84] **Inclusion bodies from recombinant bacteria as a novel system for delivery of vaccine antigen by the oral route**
M. Kesik^{*1}, H. Wedrychowicz², V. Saczynska¹, A. Plucienniczak¹; ¹*Institute of Biotechnology and Antibiotics, Poland*, ²*Witold Stefanski Institute of Parasitology Polish Academy of Sciences, Poland*
- [P85] **Live-attenuated immunotherapeutic for Hepatitis B virus infection**
S. Sulsh*, J.L. Telfer; *Emergent BioSolutions, UK*

Poster programme

Health policy

- [P86] **GEM Particles as antigen delivery vehicle: Activation of the adult- and neonatal immune system and applications in nasal vaccines**
 K. Leenhouts¹, M. van Roosmalen¹, J. Smisterova², M. Pasetti³, P. Hermans⁴, X. Saelens⁵; ¹*Mucosis BV, The Netherlands*, ²*Biomade Technology, The Netherlands*, ³*University of Maryland, USA*, ⁴*RUNMC, Netherlands*, ⁵*University of Ghent, Belgium*
- [P87] **Determinants of two immunization behaviours of British Columbia immunization providers**
 K.L. Pielak¹, V. Remple¹, C. McIntyre¹, J. Buxton¹, B. Halperin²; ¹*British Columbia Centre for Disease Control, Canada*, ²*Clinical Trials Research Center, Canada*
- [P88] **Development of a survey instrument to measure psychosocial determinants of immunization intentions of Canadian immunization providers using the theory of planned behaviour**
 K.L. Pielak¹, C. McIntyre¹, B. Halperin², J. Buxton¹, V. Remple¹; ¹*British Columbia Centre for Disease Control, Canada*, ²*Clinical Trials Research Center, Canada*
- [P89] **Are typhoid vaccines a good investment for a slum in Kolkata, India?**
 J. Cook¹, D. Sur², J. Clemens³, D. Whittington⁴; ¹*University of Washington, USA*, ²*National Institute of Cholera and Enteric Diseases, India*, ³*International Vaccine Institute, South Korea*, ⁴*University of North Carolina at Chapel Hill, USA*
- [P90] **Cost-effectiveness of influenza vaccination for children aged 6 to 59 months in The Netherlands**
 M.J. Meijboom¹, E. Buskens², A.G.S.C. Jansen³, E.A.M. Sanders³, R. van Gageldonk⁵, E. Hak³; ¹*Pharmerit BV, The Netherlands*, ²*University of Groningen, The Netherlands*, ³*University Utrecht, The Netherlands*, ⁵*National Institute for the Environment and Health, The Netherlands*
- [P91] **Bordetella pertussis infection in Catalonia, 2003-2004**
 N. Cardeñosa¹, M. Romero¹, G. Carmona¹, M. Oviedo², G. Codina³, A. Domínguez⁴; ¹*Public Health Department, Spain*, ²*CIBERESP, Spain*, ³*Hospital Vall Hebron, Spain*, ⁴*University of Barcelona, Spain*
- [P92] **Cost-effectiveness of new-generation oral cholera vaccines: A multi-country analysis**
 M. Jeuland¹, J. Clemens², J. Cook¹, D. Whittington¹; ¹*University of North Carolina - Chapel Hill, USA*, ²*International Vaccine Institute, South Korea*
- [P93] **A cost-benefit analysis of Cholera vaccination in Beira, Mozambique**
 M. Jeuland¹, M. Lucas³, J. Clemens², D. Whittington¹; ¹*University of North Carolina - Chapel Hill, USA*, ²*International Vaccine Institute, South Korea*, ³*Ministry of Science and Technology, Mozambique*
- [P94] **Model based evaluation of varicella vaccination in Italian children and adolescents assessing different intervention strategies: the burden of uncomplicated hospitalised cases**
 P. Bonanni¹, S. Boccalini¹, A. Bechini¹, A. Marocco², F. Bamfi², F. Marchetti²; ¹*University of Florence, Italy*, ²*GlaxoSmithKline S.p.A., Italy*
- [P95] **Who made what when? The supply of vaccines in the U.S. between 1986 and 2006**
 C. Layton^{*}, A. O'Connor, C. Ramirez; *RTI International, USA*
- [P96] **Public financing of vaccines in the U.S.: A review of funding**
 C. Layton^{*}, N. Mitchell; *RTI International, USA*
- [P97] **Cost-effectiveness analysis of universal childhood vaccination program against Rotavirus in Brazil**
 P.C. Soares, J. Valentim, A.M.C. Sartori^{*}, H.M.D. Novaes; *University of Sao Paulo, Brazil*
- [P98] **Cost-effectiveness analysis of universal childhood vaccination program against Varicella in Brazil**
 J. Valentim, A.M.C. Sartori^{*}, P.C. Soares, M. Amaku, R.S. Azevedo, H.M.D. Novaes; *University of Sao Paulo, Brazil*
- [P99] **Evaluation of cost-effectiveness of universal mass HPV16/18 vaccination in The Netherlands**
 V.M. Coupe^{*}, J. van Ginkel, P.J. Snijders, C.J. Meijer, J. Berkhof; *VU University Medical Centre, The Netherlands*
- [P100] **Vaccination coverage in 14-year-old adolescents in Flanders, 2005**
 C. Vandermeulen¹, M. Roelants¹, H. Theeten², A.M. Depoorter³, P. Van Damme², K. Hoppenbrouwers¹; ¹*K.U.Leuven, Belgium*, ²*Antwerp University, Belgium*, ³*Vrije Universiteit Brussel, Belgium*
- [P101] **Establishment of a second national serum bank for population-based seroprevalence studies in the Netherlands (February 2006 - June 2007)**
 L. Mollema^{*}, H.E. De Melker, J.W.M Van Weert, F.R.M. Van der Klis; *National Institute for Public Health and the Environment (RIVM), The Netherlands*
- [P102] **Sources of infection of Pertussis in infants too young to be vaccinated**
 S.C. de Greeff¹, A. Westerhof¹, F.R. Mooi², H.E. de Melker¹; ¹*National Institute for Public Health and the Environment, The Netherlands*, ²*Centre for Infectious Disease Control, National Institute for Public Health and the Environment, The Netherlands*
- [P103] Poster withdrawn